HIF-PHIs are molecular inhibitors of prolyl hydroxylase domain dioxygenases, which stimulate hypoxic induction, resulting in increased erythropoietin production and iron metabolism. Recent data from phase 2 and phase 3 studies have demonstrated the efficacy of HIPreF-PHIs in correcting and maintaining hemoglobin levels with fewer adverse cardiovascular effects as compared with ESAs in patients with CKD. Currently, several HIF-PHIs are being marketed in Asia. However, questions and concerns remain and warrant further investigation.
Preclinical and clinical studies have suggested that inhibitors of hepcidin may be beneficial for anemia in CKD, but to date, no compounds are under investigation in humans.
Learn more about CKD anemia management.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pradeep Arora. Fast Five Quiz: Management of Chronic Kidney Disease Anemia - Medscape - Apr 19, 2022.